Mazdutide
Phase 3Peptide
Eli LillyMazdutide is one of 32 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 3.
2
Indications
4
Total Trials
4
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Mazdutide
Eli LillyPhase 3
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metformin1 trial
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT07417306·912 enrolled
Type 2 Diabetes1 trial
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT07083154·420 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mazdutide. EMBL-EBI & Wellcome Sanger Institute.
- [4]